NCT06974617View on ClinicalTrials.gov

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

NARecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Sphenopalatine BlockBOTOXChronic Migraine
Interventions
DRUG

Sphenopalatine block

Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.

DRUG

Botulinum Toxin Type A

Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.

Trial Locations (1)

12613

RECRUITING

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER